ABSTRACT

Introduction Ambient ozone exposure may be adverse to health. Since the reported associations between ozone and health effects are heterogeneous and the underlying pathways are indistinct, the overall relationship remains unclear. Only a few overall syntheses of the evidence regarding ozone and health effects are available to date.

Methods and analysis We plan to summarise the current evidence on ozone-related health effects systematically. First, to identify the possible associations between ambient ozone exposure and health outcomes, we will conduct an umbrella review. PubMed, Web of Science and grey literature will be searched for systematic reviews on exposure to ambient ozone and any possible health endpoints published before 31 May 2019. Data selection and extraction will be carried out by one reviewer, and a second reviewer will check the agreement of a sample of the studies. The methodological quality of the eligible systematic reviews and level of evidence regarding ozone and every specific health effect will be evaluated. Second, for each of the identified effects with a high level of evidence, comprehensive information retrievals will be conducted, considering both epidemiological and experimental studies. The study selection and data mapping will be carried out by one reviewer and checked by the second reviewer. We will summarise the information of the filtered epidemiological and experimental studies to conduct several systematic maps presenting the currently available evidence for the specific health effect. Because the association between ozone exposure and chronic obstructive pulmonary disease (COPD) is relatively well investigated, we will at least conduct one systematic map of ozone and COPD.

Ethics and dissemination No ethical approval is required for this study. The completed umbrella review and systematic maps will be considered for publication and presentation. We will additionally upload the relevant data to publicly accessible online databases.

PROSPERO registration number CRD42019123064.

INTRODUCTION

Ambient air pollution has been considered a leading cause of the global burden of disease (GBD). According to the GBD study, air pollution was estimated to account for 4.9 million deaths (95% uncertainty interval (UI) 4.4–5.49 million) and 147.0 million (132.0–162.0 million) disability-adjusted life years (DALYs) in 2017.

Although the majority of the air pollution-related burden is attributed to particulate matter (PM) in the GBD studies, the burden from ambient ozone pollution is also alarming. In 2017, ambient ozone exposure caused 472 000 (95% UI 177 000–768 000) deaths and a loss of 7.4 million (2.7–12.0 million) DALYs. In addition, considering climate change, global warming and increased emissions of ozone precursors, the long-term ambient ozone is expected to increase in concentration. Thus, ozone-related mortality might grow in the future.

The association between ozone and chronic obstructive pulmonary disease (COPD) is regarded to be in line with the basis of evidence rules by the GBD study group, and COPD is, thus, the only one ozone-related health outcome included in the GBD study 2017. A lack of evidence for other effects is largely
explained by ozone is under investigated compared with PM, and because based on the hierarchy of evidence, the conducted epidemiological observational studies are not considered as a high quality.

Regarding the evidence, a systematic review is a standard method for summarising and analysing available evidence on health issues. Systematic reviews are regarded to be of high evidence hierarchy and of low risk of bias. Currently, as systematic reviews have synthesised a growing number of original studies, more evidence is accumulating. From these reviews, we can find out ozone exposure linked to different kinds of health effects, not only to the respiratory system but also to the cardio-cerebrovascular, central nervous system or mental health. Consequently, the possibility of tracing evidence up to date has been overwhelmed by the rapidly increased number of systematic reviews.

Remarkably, an umbrella review, systematically reviewing previously published systematic reviews, could generate a higher level of the hierarchical evidence and has attracted increasing research attention. This trend can be identified by the number of newly published umbrella reviews and protocols on various topics. An umbrella review would be a feasible way to outline the associations between ozone exposure and health effects.

On the other hand, biological mechanisms that possibly lie behind the associations reported by epidemiological studies are relatively unclear—although exposure to ozone has been postulated to be associated with adverse health effects via oxidative stress and inflammatory response. More and more efforts are trying to bridge the gap between epidemiological associations and biological relevance, yet they are largely restricted to descriptive discussion of the results from relevant experimental studies or narrative review of studies with a similar setting. There still is an absence of any systematic syntheses of evidence on a specific ozone-related health effect.

Therefore, a systematic map, or a systematic evidence map, which uses systematic search and strategical selection but seeks no evidence synthesis, is an appropriate emerging method to comprehensively summarise and catalogue the ozone-related broad and miscellaneous evidence from original experimental studies, as well as original epidemiological studies.

On this background, we aim to perform an umbrella review on ambient ozone exposure and health effects by systematically reviewing existing systematic reviews. We will additionally supplement those significant ozone-effect pairs filtered from the umbrella review with original epidemiological and experimental evidence, to provide a more comprehensive picture on ozone and health. This study will (1) identify exposure-related health effects of ambient ozone by an umbrella review and (2) integrate current available epidemiological studies, and cross-reference the effects with experimental studies, by conducting systematic maps.

METHODS AND ANALYSIS
This project has been registered on the International Prospective Register of Systematic Reviews (https://www.crd.york.ac.uk/prospero/) on 24 April 2019. The present protocol was developed and modified in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 checklist and the guidance on systematic maps published by the Collaboration for Environmental Evidence.

Patient and public involvement
This study will have no patient or public involvement and will collect no primary data.

Study design
The project will be divided into two processes. The first process will be an umbrella review. In other words, a systematic review to identify the published systematic reviews on the association between ambient ozone exposure and any health endpoints. We will further grade the evidence of ozone-effect pairs based on parameters from the systematic reviews with meta-analysis. The second process will be the development of systematic maps for the specific health effects with high evidence levels identified by the umbrella review. For example, if COPD were to be identified as an ozone-related health effect with a high evidence level, we would conduct a systematic map of ozone exposure and COPD. Every systematic map will contain all of the published original epidemiological studies, as well as the currently available experimental studies of the specific health effect.

Umbrella review
In our registered protocol, we specified that the first process will contain three search paths: a systematic review of systematic reviews, of the burden of disease studies and of relevant study reports. The current protocol has been renamed ‘systematic review of systematic reviews’ to ‘umbrella review’, and contains no systematic review of the burden of disease studies. The detailed table of PRISMA is listed in the Supplementary (online supplementary table S1).

The process of the umbrella review will be guided by the PRISMA guideline. Given no agreed method for conducting an umbrella review, our methodology will be performed in accordance with previously published umbrella review on risk factors (eg, dietary factor, lifestyle, medical history and socioeconomic status) and health effects.

Eligibility criteria
Types of participant
The general human population will be considered, regardless of age, sex, race, region, as well as health states.

Types of exposure (intervention)
The exposure is ambient ozone. Indoor and occupational exposure will not be considered.
Types of comparator
Comparisons are varied across studies. Generally, the comparison is between the participants or periods with lower levels of ambient ozone exposure and the more highly exposed populations or periods.

Types of outcome
Any possible health effects, such as symptoms, conditions, diseases, morbidity, mortality, considering both the long-term or chronic effects and the short-term or acute effects, will be our outcomes of interest. Additionally, several possible indirect indicators, such as restricted activity days, days with symptoms or hospital admissions, will be involved where applicable.

Inclusion criteria
We will include the systematic reviews that investigated ambient ozone exposure and health effects, published before 31 May 2019, written in English or German.

Exclusion criteria
We will not include articles, abstracts, dissertations or letters. Cell or animal studies and botanical studies will be excluded. The papers about indoor or occupational ozone exposure and clinical studies on ozone therapy will not be considered.

Information source and search strategy
Databases to be searched will include PubMed and Web of Science. Combinations of both free terms and Medical Subject Headings (MeSH) connected with ‘ozone’ and ‘systematic review’ or ‘meta-analysis’ will be used for search (online supplementary table S2).

Reference lists of included studies will be searched manually for potentially relevant papers. Additionally, grey literature, such as reports from relevant institutes, will be searched on their websites. A list of relevant institutes (online supplementary table S3) is adopted and updated from a previous project.

Study management and selection
The assessed studies will be imported to EndNote V.X8 software. After deduplication, the selection process contains two stages: an initial screening of the titles and abstracts based on the aforementioned criteria and followed by a second screening of the full texts of the papers filtered by the initial screening. The entire process will be illustrated by a PRISMA flow chart.

One member of the reviewer team (TZ) will independently conduct the study selection. A second reviewer (NSM) will check the agreement of a randomly selected sample of the studies (at least 10%). The strength of the agreement will be calculated by the Kappa score. Further disagreements will be determined through consensus by a third member (JH).

Data extraction
A predesigned Microsoft Excel table will be revised and used for extracting data from the selected studies (online supplementary file 2). The extracted information will include the first author, year of publication, journal, type of study (systematic review with or without meta-analysis), search results (name of database, date of search, number of hits), key information of included studies (the overall population–exposure–comparator–outcome (PECO) or population–intervention–comparator–outcome (PICO) statement) and the summarised ozone-related results of the included studies, as well as the method of quality assessment and/or risk of bias used by the studies. When the data of interest are incomplete, the corresponding author will be contacted for acquiring additional information. Furthermore, for the involved systematic reviews with meta-analysis, data on the total number of cases, effect estimates (eg, OR or risk ratio), confidence interval (CI), p value, as well as results about heterogeneity (eg, the I² statistic, the Q value and the associated p value) and results on publication bias (eg, Egger test) will be recorded. One member of the reviewer team (TZ) will extract the information. The second reviewer (NSM) will check the agreement of a randomly selected sample of the studies (more than 10%).

Study assessment
We will adopt ‘a measurement tool to assess systematic reviews 2’ (AMSTAR2) criteria to evaluate the methodological quality of included systematic reviews and meta-analyses. The AMSTAR2 contains 16 items in total, and 7 out of them are considered as critical domains. The assessment by AMSTAR2 generates no score but an overall rating of the review, that is, high, moderate, critically low and low. A detailed description of AMSTAR2 can be accessed elsewhere.

Data analysis
For the included systematic reviews, we will qualitatively describe their main results in a summary table. The table will contain the first author, year of publication, key information of included studies (the overall PECO or PICO statement), the summarised ozone-related results and the results of AMSTAR2. Moreover, information on the total number of cases, effect estimates, CI, p value, heterogeneity and publication bias will be listed for the systematic reviews with meta-analysis.

Apart from the descriptive information, quantity analysis will be conducted for meta-analysis where applicable. In case two or more studies present overlapping datasets of original studies on the same health effect, we will retain the study with the largest datasets. A random effect p value of a meta-analysis will be mainly adopted. A prediction interval indicating the heterogeneity between studies and estimating the uncertainty of effect estimate in a future new study will be calculated based on the extracted data of the identified meta-analysis.

A standard formula for a prediction interval based on k studies can be obtained as...
Zhao T, et al. BMJ Open 2020;10:e034854. doi:10.1136/bmjopen-2019-034854

Table 1 Levels of evidence

| Evidence      | Class       | Requirement                                                                 |
|---------------|-------------|-----------------------------------------------------------------------------|
| Convincing    | Class I     | Number of cases >1000, meta-analysis p value <10^{-6}, between study heterogeneity $I^2$ <50% and 95% prediction interval excluding the null; no detected publication bias |
| Highly suggestive | Class II   | Number of cases >1000, meta-analysis p value <10^{-6}, the largest study with a statistically significant effect and class I criteria not meet |
| Suggestive    | Class III   | Number of cases >1000, meta-analysis p value <10^{-3} and class I or II criteria not meet |
| Weak          | Class IV    | Meta-analysis p value <0.05 and classes I–III criteria not meet               |
| Non-significant | Null       | meta-analysis p value > 0.05                                                 |

\[
\mu \pm t_{\alpha/2} \times \frac{SE(\mu)}{\sqrt{k}} = \left[ \bar{y}^2 + SE(\bar{y})^2 \right]^{1/2}
\]  

(1)

Where $\frac{SE(\mu)}{\sqrt{k}}$ is a point estimate of the heterogeneity variance, $t_{\alpha/2}$ is the 100 $(1 - \frac{SE(\mu)}{\sqrt{k}})$% percentile of the $t$-distribution with $k$–2 degrees of freedom.\(^{31}\)

In order to compare the different effect estimates across studies, we will recalculate the various effect estimates into ORs.\(^{33,39}\)

Finally, a classification of levels of evidence (table 1) summarised by the previously published umbrella reviews\(^{35–37}\) will be used and updated to grade the ozone–health effect pairs. The health effects classified to have classes I–III evidence will be considered to have a high level of evidence.

Synthesis of results

The results of this umbrella review will include the flow chart of the literature search process, the aforementioned summary table, and a synthesis table for meta-analysis containing the results of the quantitative analysis. We anticipate discussing the overall descriptive results of the assessed systematic reviews, and the classification of levels of evidence regarding ozone–health effect pairs.

Systematic map

Based on the results of the umbrella review, the second process of the project will focus on the identified ozone-related health outcomes with high evidence levels (class I, II or III). However, given COPD is widely investigated and included already in the GBD study,\(^2\) we will conduct a systematic map of ozone and COPD regardless of the confidence level stemmed from the umbrella review.

Unlike the registered protocol,\(^28\) we revised the second process of this project. The updated systematic map will cover both the published epidemiological studies and experimental studies. The current PRISMA-P table in Supplementary (online supplementary table S4) is adopted from the RepOrting standards for Systematic Evidence Syntheses\(^^{42}\) and the journal Environment International.\(^{31}\)

A revised PRISMA reporting guidelines and checklist\(^{43}\) will be used to guide the process of systematic maps. The planned systematic maps will mirror the guidelines established by the National Toxicology Program/Office of Health Assessment, Development and Translation (OHAT)\(^{44}\) as well.

Eligibility criteria

Types of PECO or PICO

A general PECO or PICO statement for systematic maps is listed in table 2.

Inclusion and exclusion criteria

The studies included in systematic maps should contain original research investigating ozone exposure and the health effects with high levels of evidence identified by the umbrella review. The epidemiological, experimental or toxicological studies in line with the PECO or PICO statement will be included. Articles on clinical ozone therapy and botanical studies will be excluded. Reviews, letters or conference abstracts will not be involved in systematic maps.

We will have no requirements on publication dates for a systematic map. Articles published in the English language will be focused on.

Information source and search strategy

The search will be conducted in PubMed and Web of Science, using both free terms and MeSH terms for ozone and the identified health effects. Reference lists of included articles and systematic reviews on the same topic identified by the umbrella review will be searched manually for potentially relevant papers.
Since the results of the umbrella review will provide outcomes of systematic maps, we currently cannot report the entire search strategy. However, regarding the case of COPD, a general strategy would be “(ozone OR O3) AND (“chronic obstructive pulmonary disease” OR COPD)”.

**Study management and selection**

One member of the review team (TZ) will conduct the study selection. The second reviewer (NSM) will check the agreement of a sample of the studies (more than 10%). A third member (JH) would be involved in the case of disagreement. The assessed studies will be imported to EndNote V.X8 software. After deduplication, we will upload the data to Health Assessment Workspace Collaborative (HAWC, https://hawcproject.org/) for management and screening. HAWC is an online open-source platform providing a transparent method for study selection, data extraction, data assessment, evidence synthesis and data visualisation.

**Data coding strategy**

After the full-text screening, a coding tool will be designed and updated to extract and record data from the included studies. Based on the OHAT protocol, extracted information could involve: study identification information (first author, year of publication), type of study (epidemiological or animal, or ex vivo/in vitro study), key information of included studies (the overall PECO or PICO statement), as well as the summarised conclusions of a study. Additional information about conflict of interest, funding statements and acknowledgements will be extracted likewise. Similarly, one reviewer (NSM) will check the other’s (TZ) work with a sample of the studies (more than 10%).

**Study assessment and data mapping**

For the systematic maps, no assessments or analyses will be considered.

For a specific health effect, a systematic map will present evidence assessed from epidemiological, human exposure, animal and ex vivo/in vitro studies separately. A table will be prepared for narratively mapping the extracted data. We will also present the result by a display in Tableau Public (https://public.tableau.com/en-us/s/). An interactive map contains the above-mentioned information in the table will be easily and freely accessed online.

**Synthesis of results**

We plan to develop systematic maps for each health effect identified via the umbrella review that is supported by a high evidence level. The results of a systematic map will include a flow chart recording the process of study selection, a table presenting the general information and the online display. Regarding a determined ozone-related health effect, we will discuss the available evidence, current paucity and future suggestions.

**PILOT STUDY**

**Information retrieval for the umbrella review**

We conducted a preliminary search for the umbrella review. Our search strategy yielded 1867 hits on 31 May 2019. After deduplication and a primary screening, this number was reduced to 100 (figure 1).

**Search string of a systematic map on COPD**

We conducted a presearch for the systematic map on COPD in PubMed with the string “(ozone[tiab]
OR $O_3$ (tiab) AND (“chronic obstructive pulmonary disease” (tiab) OR COPD (tiab)” on 22 September 2019. There were 254 hits.

ETHICS AND DISSEMINATION

Since this study will only collect and analyse data from published and accessible studies, approval from an ethics committee is not required.

The umbrella review and systematic maps will be disseminated in reports and peer-reviewed journals, and if applicable, will also be presented at relevant conferences. The data of systematic maps would be publicly available at the website of HAWC and Tableau Public.

Author affiliations

1Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

2Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung Research, Munich, Germany

3Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

4Department of Applied Social Sciences, Munich University of Applied Sciences, Munich, Germany

5Institute of Psychology, Jagiellonian University, Krakow, Poland

6Department of Public Health and Health Technology Assessment, University for Health Sciences, Medical Computer Science and Technology, Hall in Tirol, Austria

7Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia

Acknowledgements

We are grateful to Dr James P. K. Rooney for proofreading our manuscript.

Contributors

TZ, NS-M, IM and JH had the original idea of this work. TZ drafted the protocol with assistance from NS-M, IM, CJ, and DN provided revision in the editing and write-up process. All authors approved the final version of the protocol. TZ is the guarantor of the umbrella review and systematic maps. NSM and JH contributed equally as last author.

Funding

The planned umbrella review and systematic maps are supported by the project ‘Quantifizierung der Krankheitslast verursacht durch Ozon-Exposition in Deutschland für die Jahre 2007–2016’ on behalf of the German Environment Agency (UBA), funded by the Federal Ministry of Environment, Nature Conservation, and Nuclear Safety (Bundesministerium für Umwelt, Naturschutz und nukleare Sicherheit, BMU, grant number 0371622080). This work is supported by the Bavarian Academic Forum (BayWISS) - Doctoral Consortium ‘Health Research’ and is funded by the Bavarian State Ministry of Science and the Arts. TZ is supported by the China Scholarship Council (CSC, grant number 201708120056). IM is supported from the ‘NeuroSmog: Determining the impact of air pollution on the brain’ (Nr. POIR.04.04.00-1763/18-00) which is implemented as part of the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme.

Competing interests

No.

Patient and public involvement

Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID

Tianyu Zhao

http://orcid.org/0000-0002-2696-273X

REFERENCES

1 Cohen AJ, Brauer M, Burnett R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the global burden of diseases study 2015. Lancet 2017;389:1907–18.

2 Stanaway JD, Ahsin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1923–94.

3 Forouzanfar MH, Ahsin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016;388:1659–724.

4 Goktekin E, Ahsin A, Alvis-Guzman N, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet 2017;390:1345–422.

5 European Environment Agency. Air pollution due to ozone: health impacts and effects of climate change. Copenhagen: European environment agency (EEA), 2015. Available: https://www.eea.europa.eu/data-and-maps/indicators/air-pollution-by-ozone-2-assessment [Accessed 07 Aug 2020]

6 Chen K, Fiore AM, Chen R, et al. Future ozone-related acute excess mortality under climate and population change scenarios in China: a modeling study. PLoS Med 2018;15: e1002598.

7 Biondi–Zoccali G. Umbrella reviews: evidence synthesis with Overviews of reviews and Meta-Epidemiologic studies. Cham, Switzerland: Springer International, 2016.

8 Shah ASV, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet 2013;382:1039–48.

9 Shah ASV, Lee KK, McAllister DA, et al. Short term exposure to air pollution and stroke: systematic review and meta-analysis. BMJ 2015;350:h1295.

10 Croze ML, Zimmer L. Ozone atmospheric pollution and Alzheimer’s disease: from epidemiological facts to molecular mechanisms. J Alzheimers Dis 2016;62:503–22.

11 Hu C–Y, Fang Y, Li F–L, CY H, FL L, et al. Association between ambient air pollution and Parkinson’s disease: systematic review and meta-analysis. Environ Res 2019;168:448–59.

12 Zhao T, Markeych I, Romanos M, et al. Ambient ozone exposure and mental health: a systematic review of epidemiological studies. Environ Res 2018;165:459–72.

13 Fan S–J, Heinrich J, Bloom MS, et al. Ambient air pollution and depression: a systematic review with meta-analysis up to 2019. Sci Total Environ 2020;701:134721.

14 Bastian H, Glasscous P, Chalmers I. Seventy-Five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 2010;7:e1000326.

15 Nagendrababu V, Duncan HF, Whitworth J, et al. Comparing the anaesthetic efficacy of articaine with lidocaine in patients with irreversible pulpitis: an umbrella review. Int Endod J 2019.

16 Grabovac I, Veronese N, Stefanac S. Human immunodeficiency virus infection and diverse physical health outcomes: an umbrella review of meta-analyses of observational studies. Clinical infectious diseases, an official publication of the Infectious Diseases Society of America, 2019.

17 Abrams D, McNair M. Quality of life in patients with advanced heart failure and an implanted left ventricular assist device: an umbrella review protocol. JBI Database System Rev Implement Rep 2019;17:2115–21.

18 Lindekilde N, Nefs G, Henriksen JE, et al. Psychiatric disorders as risk factors for the development of type 2 diabetes mellitus: an umbrella review protocol. BMJ Open 2019;9:e024981.

19 Gan J, Ma D, Xiong T. Efficacy and safety of leveteracetam in children with epilepsy: protocol for an umbrella: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials. BMJ Open 2019;9:e029811.

20 Zhao T, Markeych I, Standl M, et al. Short-term exposure to ambient ozone and inflammatory biomarkers in cross-sectional studies of children and adolescents: results of the GINplus and LISA birth cohorts. Environ Pollut 2019;255:113264.
21. Pirozzi C, Sturrock A, Weng H-Y, et al. Effect of naturally occurring ozone air pollution episodes on pulmonary oxidative stress and inflammation. *Int J Environ Res Public Health* 2015;12:5061–75.
22. Zhao T, Markeych I, Standi M, et al. Ambient ozone exposure and depressive symptoms in adolescents: results of the GINIplus and LiSA birth cohorts. *Environ Res* 2019;170:73–81.
23. Kaufman JA, Wright JM, Rice G, et al. Ambient ozone and fine particulate matter exposures and autism spectrum disorder in metropolitan Cincinnati, Ohio. *Environ Res* 2019;171:218–27.
24. Weisenberg H, Zhao T, Heinrich J. Combinations of epidemiological and experimental studies in air pollution research: a narrative review. *Int J Environ Res Public Health* 2020;17:385.
25. James KL, Randall NP. A methodology for systematic mapping in environmental sciences. *Environ Evid* 2016;5:7.
26. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J* 2009;26:91–108.
27. Wolfe TAM, Whaley P, Hatali C, et al. Systematic evidence maps as a novel tool to support evidence-based decision-making in chemicals policy and risk management. *Environ Int* 2019;130:104871.
28. Zhao T, Markeych I, Nowak D. PROSPERO International prospective register of systematic reviews, 2019. Ambient ozone exposure and health effects: a systematic review of epidemiological analyses (CRD42019123064). Available: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=123064 [Accessed 07 Aug 2020].
29. Shamsee L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015. elaboration and explanation. *BMJ* 2015;349:g7647.
30. Environmental Evidence. Preparing your manuscript: systematic MAP protocol: environmental evidence, 2017. Available: https://environmentalvidencejournal.biomedcentral.com/submission-guidelines/preparing-your-manuscript/systematic-map-protocol [Accessed 07 Aug 2020].
31. Environment International. Guidance notes for authors of systematic reviews, systematic maps and other related manuscripts: environment international, 2017. Available: https://www.elsevier.com/journals/environment-international/0160-4120/guidance-notes [Accessed 07 Aug 2020].
32. Radua J, Ramella-Gravaro V, Ioannidis JPA, et al. What causes psychosis? an umbrella review of risk and protective factors. *World Psychiatry* 2018;17:49–66.
33. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. *Evid Based Ment Health* 2018;21:95–100.
34. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2653.
35. Bellasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol* 2015;14:263–73.
36. Bellou V, Bellasis L, Tzoulaki I, et al. Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. *Parkinsonism Relat Disord* 2016;23:1–9.
37. Bellou V, Bellasis L, Tzoulaki I, et al. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. *Alzheimers Dement* 2017;13:406–18.
38. Schneider A, Curyx J, Breitner S, et al. Quantifizierung von umweltbedingten Krankheitslasten aufgrund Der Stickstoffdioxid-Exposition in Deutschland. Dessau-Roßlau, Germany: Umweltbundesamt, 2018. https://www.umweltbundesamt.de/publicationen/quantifizierung-umweltbedingten
39. Bobrovitz N, Henehan C, Onakpoya I, et al. Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. *BMC Med* 2018;16:115.
40. Shea B, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
41. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc* 2009;172:137–59.
42. ROSES. Reporting standards for systematic evidence syntheses. *roses for systematic MAP protocols. RepOrting standards for Systematic Evidence Syntheses, 2017. https://www.roses-reporting.com/systematic-map-protocols*
43. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
44. OHAT. Handbook for conducting systematic reviews. National Institute of Environmental Health Sciences, 2015. *Office of Health Assessment and Translation (OHAT) Division of the National Toxicology Program National Institute of Environmental Health Sciences, 2015.*
45. Matta K, Ploteau S, Coumoul X, et al. Associations between exposure to organochlorine chemicals and endometriosis in experimental studies: a systematic review protocol. *Environ Int* 2019;124:400–7.
46. Shapiro A. HAWC: health assessment Workspace collaborative. *Research Triangle Park, NC; National Toxicology Program, 2015.*
47. Pelch KE, Reade A, Wolfe TAM, et al. PFAS health effects database: protocol for a systematic evidence MAP. *Environ Int* 2019;130:104851.